Stockscreener 앱 받기
27.87
1.75%
0.48
시간 외 거래:
28.71
0.84
+3.01%
전일 마감가:
$27.39
열려 있는:
$27.52
하루 거래량:
2.25M
Relative Volume:
1.15
시가총액:
$4.60B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
14.29
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
+3.49%
1개월 성능:
-4.06%
6개월 성능:
-18.91%
1년 성능:
+0.47%
1일 변동 폭
$27.38
$28.28
1주일 범위
$26.40
$28.28
52주 변동 폭
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
27.87 | 4.52B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
146.93 | 65.35B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.09 | 47.75B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.40 | 41.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.38 | 21.43B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
403.68 | 18.00B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
VIX Spike: What analysts say about Alkermes plc stockJuly 2025 Highlights & Long-Term Capital Growth Strategies - خودرو بانک
Alkermes plc $ALKS Shares Purchased by Voya Investment Management LLC - MarketBeat
Leading companies in this space include Aadi Bioscience, - openPR.com
Analysts Set Alkermes plc (NASDAQ:ALKS) Target Price at $41.85 - MarketBeat
Fed Watch: Is Alkermes plc stock undervalued right nowJuly 2025 Big Picture & Low Risk High Reward Trade Ideas - خودرو بانک
Pullback Watch: Will Alkermes plc outperform during market rallies2025 Pullback Review & Accurate Buy Signal Alerts - خودرو بانک
Rate Cut: What is the implied volatility of Alkermes plcJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - خودرو بانک
Bearish Setup: What is the implied volatility of Alkermes plcJuly 2025 WrapUp & Fast Entry High Yield Tips - خودرو بانک
Alkermes' CFO Iain Brown passes away - MSN
Alkermes plc $ALKS Shares Acquired by Intech Investment Management LLC - MarketBeat
Whale Trades: Can Alkermes plc maintain sales growthJuly 2025 Update & Verified Entry Point Signals - خودرو بانک
Tech Rally: Is Alkermes plc stock technically oversoldJuly 2025 Closing Moves & Free Technical Confirmation Trade Alerts - خودرو بانک
Market Review: What chart patterns are forming on WM Technology Inc. Equity WarrantEarnings Risk Summary & Community Shared Stock Ideas - خودرو بانک
Alkermes (NASDAQ:ALKS) Earns "Neutral" Rating from HC Wainwright - MarketBeat
AQR Capital Management LLC Sells 279,276 Shares of Alkermes plc $ALKS - MarketBeat
Amundi Cuts Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Given New $35.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Alkermes (NASDAQ:ALKS) Reaches New 1-Year LowHere's Why - MarketBeat
Alkermes Sees Unusually Large Options Volume (NASDAQ:ALKS) - MarketBeat
Acadian Asset Management LLC Has $29.10 Million Position in Alkermes plc $ALKS - MarketBeat
Baird Financial Group Inc. Purchases New Shares in Alkermes plc $ALKS - MarketBeat
Alkermes appoints Joshua Reed as new CFO effective Monday By Investing.com - Investing.com Australia
Alkermes appoints Joshua Reed as new CFO effective Monday - Investing.com India
Alkermes appoints new CFO - MSN
Alkermes says on Sept 9, unit granted Amneal rights to sell generic version of VivitrolSEC filing - MarketScreener
Alkermes Appoints Joshua Reed as New CFO - TipRanks
Alkermes plc Appoints Joshua Reed as Chief Financial Officer, Effective Date Is September 15, 2025 - MarketScreener
Alkermes Appoints Joshua Reed as Chief Financial Officer - Sharecast News
Alkermes (ALKS) Appoints Joshua Reed as New CFO - GuruFocus
Alkermes appoints Joshua Reed as chief financial officer - MarketScreener
30-Year Biotech Finance Veteran Joshua Reed Joins Alkermes as CFO After Bristol Myers Leadership - Stock Titan
While Shareholders of Alkermes (NASDAQ:ALKS) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - Eastern Progress
Fred Alger Management LLC Takes $1.24 Million Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Launch of 8th Annual Alkermes Pathways Resear - GuruFocus
Potential Impact on Alkermes (ALKS) from RFK Jr.'s Possible Depa - GuruFocus
How RFK Jr.'s Potential Exit Could Benefit Alkermes (ALKS) - GuruFocus
JP Morgan Maintains Neutral Rating for ALKS and Raises Price Tar - GuruFocus
December 2026 Options Now Available For Alkermes (ALKS) - Nasdaq
Can Alkermes plc stock outperform in a bear market2025 Risk Factors & Stepwise Trade Signal Guides - Lancaster City Council
HC Wainwright & Co. Reiterates Neutral Rating for ALKS | ALKS St - GuruFocus
Alkermes Announces Positive Phase 2 Study Results - MSN
Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Alkermes plc $ALKS Shares Acquired by Canada Pension Plan Investment Board - MarketBeat
Is Alkermes plc stock showing strong momentumJuly 2025 Spike Watch & Reliable Breakout Forecasts - 뉴스영
Alkermes stock hits 52-week low at 25.31 USD By Investing.com - Investing.com Canada
Alkermes (ALKS) Reports Promising Results from Phase 2 Narcoleps - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com Canada
Takeda and Alkermes share OX2R drug data for narcolepsy - Yahoo Finance
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.07%
0.63%
자본화:
|
볼륨(24시간):